
Lung cancer is the leading cause of death zzso Current treatment zzso including chemotherapy, zzso and surgery, provide only limited improvement in the natural course of this zzso zzso the development of new therapeutic strategies is highly zzso This review focuses on recent achievements on a novel class of zzso drugs targeting the zzso zzso Growth Factor zzso The zzso family is a group of four structurally similar growth factor receptors with zzso activity zzso zzso zzso zzso which zzso upon binding with a number of zzso including zzso zzso Growth zzso and zzso zzso Growth zzso allowing downstream zzso of zzso zzso zzso of zzso and zzso is frequently found in zzso lung cancer zzso which accounts for over zzso of all zzso lung tumors, and has been associated with a worse clinical zzso New agents developed to inhibit zzso function include zzso zzso and zzso zzso zzso zzso In this review, results of most recent clinical with zzso zzso including zzso zzso such as zzso zzso zzso zzso and others zzso zzso zzso and zzso zzso such as zzso zzso zzso zzso zzso zzso and others zzso zzso are zzso In particular, final results of phase II zzso 1 and 2) and III zzso 1 and 2) studies of zzso are zzso In zzso trials zzso single agent in patients zzso with zzso there was clear evidence of tumor regression, symptoms improvement and overall clinical benefit, whereas in the two zzso trials zzso in combination with standard zzso chemotherapy in zzso zzso zzso did not improve either survival or other clinical zzso zzso explanations for these contradictory results and future perspectives are zzso 

